Abbott, St. Jude Medical grow cardiovascular products alliance

April 23, 2012
Building upon an agreement that began in 2008, Abbott Laboratories (NYSE: ABT) and St. Jude Medical (NYSE: STJ) have formed Choice Alliance, a multi-year joint initiative that provides mutual US customers access to a portfolio of interventional cardiology, cardiac rhythm management, electrophysiology, and intravascular imaging and diagnostic technologies.

Building upon an agreement that began in 2008, Abbott Laboratories (NYSE: ABT; Abbott Park, IL) and St. Jude Medical (NYSE: STJ; St. Paul, MN) have formed Choice Alliance, a multi-year joint initiative that provides mutual US customers access to a portfolio of interventional cardiology, cardiac rhythm management, electrophysiology, and intravascular imaging and diagnostic technologies.

The alliance includes Abbott's coronary and endovascular product portfolios, including its Xience everolimus eluting coronary stents, and St. Jude Medical's portfolio of electrophysiology, cardiac rhythm management, and cardiology technologies, including ablation catheters, pacemakers, implantable cardioverter defibrillators (ICDs), leads, fractional flow reserve (FFR) lesion assessment technology, and optical coherence tomography (OCT) imaging products. Under the terms of the alliance, the two companies will jointly promote each other's product offerings when developing contract solutions with hospital customers in the United States, enabling both companies to present a combined comprehensive cardiovascular product portfolio. In addition, a separate distribution agreement between the two companies grants Abbott the rights to distribute St. Jude Medical's Ilumien PCI optimization system, which integrates FFR and OCT, as well as the RadiAnalyzer Xpress measurement system, in the United States.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Follow OptoIQ on your iPhone; download the free app here.

Subscribe now to BioOptics World magazine; it's free!

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)

Sponsored Recommendations

Ask the Expert: Building Better Laser Micromachining Systems

Dec. 8, 2023
Dr. Cliff Jolliffe, Head of Strategic Marketing, Industrial Automation, Physik Instrumente (PI), fields questions about integrating controls for different motion systems and lasers...

Video: December 8, 2023 Photonics Hot List

Dec. 8, 2023
In this episode, we cover a microscopy method that hits uncharted cell territory, drone-based imaging for solar farm inspection, soliton microcombs that boost conversion efficiency...

China’s industrial laser market shows steady growth in turbulent times

Dec. 8, 2023
This in-depth market update focuses on trends in laser processing and industrial lasers while touching on what to expect in the ultrafast laser, fiber laser, LiDAR, and handheld...

What does it take to land venture capital for photonics-driven startups?

Dec. 7, 2023
Capital to grow a startup company can come from many sources: contract and non-recurring engineering (NRE) funding, angels and friends, customer upfront payments, and venture ...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!